



EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

FIRM COMMITMENTS FOR \$12.0 MILLION PLACEMENT & LAUNCH OF SPP OFFER

Key Highlights:

- **EMVision to raise \$12.0 million via Placement, with strong support received from institutional and sophisticated new and existing investors**
- **Strategic shareholder Keysight Technologies (NYSE:KEYS) has subscribed pro-rata under the total capital raising size**
- **Funds raised will enable the Company to advance through major milestones for the emu™ (in-hospital) and First Responder (pre-hospital) programs over FY26 and FY27**
- **EMVision is well funded to execute on its clinical, regulatory and market access program**
- **Launch of Share Purchase Plan for Eligible Shareholders**

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) is pleased to announce that it has received firm, binding commitments from institutional, sophisticated and professional investors for \$12.0 million (before costs) under a placement of fully paid ordinary shares (“Shares”) at an issue price of \$1.94 per share (“New Shares”), together with an entitlement to apply for free attaching options exercisable at \$3.40 each and expiring 2 years from the issue date (“Placement Attaching Options”) on a 3-for-4 basis (together, the “Placement”). Subject to satisfying the ASX requirements for quotation, the Company will apply for quotation of the Placement Attaching Options.

The Company appreciates and recognises the ongoing support of its existing retail shareholder base and is pleased to announce that, in addition to the Placement, it will also be offering a Share Purchase Plan (“SPP”) to Eligible Shareholders to raise up to \$1 million (before costs), with the ability to accept oversubscriptions capped at a total of \$2 million (before costs).

The SPP offers Eligible Shareholders an opportunity to purchase up to \$30,000 worth of Shares on the same terms as the Placement (“SPP Shares”) without incurring any brokerage, transaction, or commission costs. Participants in the SPP will also receive free attaching options on the same terms as the Placement Attaching Options (“SPP Attaching Options”).

Funds raised will be deployed over FY26 and FY27 to advance the Company through major milestones, including supporting FDA submission and initial commercialisation activities for the emu™ device, and advancing the First Responder program through clinical trials, production readiness and regulatory preparation.

EMVision’s CEO and MD, Scott Kirkland, said: “We are delighted to receive the ongoing support of our existing shareholder base, including Keysight Technologies, and welcome new institutional and sophisticated investors onto our register. Funds raised allow EMVision to progress our clinical, regulatory and go-to-market activities, while maintaining a strong balance sheet as we advance towards market access and commercialisation.”

Placement Details

EMVision has successfully raised \$12.0 million (before costs) through the placement of 6,185,567 New Shares to institutional, sophisticated and professional investors, including existing shareholders, at an issue price of \$1.94 per share, together with three (3) free attaching Placement Attaching Options for every four (4) New Shares issued.

The Placement Attaching Options and the SPP Attaching Options (together, the “Options”) will be offered under a prospectus to be lodged by EMVision with ASIC and the ASX (“Options Prospectus”). The listing of the Options is subject to satisfaction of ASX quotation requirements. In the event the quotation requirements are not met, the Options will be issued as unlisted options.

The New Shares issued pursuant to the Placement are being issued under the Company’s placement capacity pursuant to Listing Rule 7.1A and the Placement Attaching Options are being issued under the Company’s Listing Rule 7.1 placement capacity. The New Shares will rank equally with existing Shares on issue.

The offer price of \$1.94 per New Share represents a:

- 16.4% discount to the last trade price of \$2.32 on 12 September 2025; and
- 6.6% discount to the 15-day volume weighted average market price of \$2.08

Barrenjoey Markets Pty Limited and Bell Potter Securities Ltd acted as Joint Lead Managers to the Placement. The Placement was not underwritten.

SPP Offer Details

Shareholders who were registered as the holder of Shares as at 7:00pm AEST on Tuesday, 16 September 2025 (“Record Date”) and whose registered address is in Australia (“Eligible Shareholders”) will be offered the opportunity to subscribe for a maximum of \$30,000 worth of SPP Shares, together with 3 free attaching SPP Attaching Options for every 4 SPP Shares issued at the same price as under the Placement.

The SPP Shares issued pursuant to the SPP will be issued in compliance with Listing Rule 7.2, exception 5 pursuant to an SPP offer booklet (“SPP Offer Booklet”) and will not utilise the Company’s placement capacities under ASX Listing Rules. The SPP Attaching Options will be offered under an Options Prospectus and will utilise the Company’s 15% placement capacity pursuant to Listing Rule 7.1. The SPP Shares will rank equally with existing Shares on issue.

The SPP is not underwritten.

Indicative Placement and SPP Offer Timetable*

Event	Date
Record Date for SPP	7:00pm AEST on Tuesday, 16 September 2025
Settlement of New Shares issued under the Placement	Tuesday, 23 September 2025
Allotment of New Shares issued under the Placement	Wednesday, 24 September 2025
Despatch of SPP Offer Booklet and Options Prospectus	Monday, 29 September 2025
Closing Date of SPP	Thursday, 23 October 2025
Announcement of Results of SPP	Thursday, 30 October 2025
Allotment of SPP Shares and Options	Thursday, 30 October 2025
Despatch of Holding Statements – SPP Shares & Options	Thursday, 30 October 2025

*The above timetable is indicative only and remains subject to change at EMVision’s discretion. The commencement of trading and quotation of New Shares, SPP Shares and Options is subject to confirmation from the ASX. The Company reserves the right to amend this timetable at any time without

notice, subject to *the Corporations Act 2001* (Cth), Listing Rules and other applicable laws. Accordingly, Eligible Shareholders are encouraged to submit their Application Forms as early as possible.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys	Scott Kirkland
Investors & Media	CEO and Managing Director
+61 400 400 380	+61 2 8667 5337
andrew.keys@keysthomas.com	skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our aim is to develop portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.